Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

-- Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources. -- The deal could be finalized in the ...

German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared 12% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions to acquire the cancer and rare disease drugmaker.